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ABSTRACT
Hematopoietic stem cell transplantation (HSCT) is being used to treat a wide spectrum of clinical disorders
but opportunistic infection remains an important factor determining outcomes for these patients. Nontuber-
culous mycobacterial (NTM) infections are being reported more frequently in HSCT recipients and the
incidence of NTM infections in adult recipients is reported to be 0.4%-4.9%. However, the incidence and
severity of NTM infections are less well described in pediatric HSCT recipients. Centers for Disease Control
and Prevention guidelines were used to define definite and probable NTM infection among 132 children
undergoing 169 HSCT between January 2000 and December 2004 at our institution. NTM infection was
diagnosed in 5 of 132 pediatric recipients (3.8%). There were no NTM infections diagnosed in the autologous
HSCT recipients and the incidence of NTM in allogeneic HSCT recipients was 6.4% (95% confidence interval,
0.8-11.9). The mean age of the HSCT recipients who developed NTM infections was 8 years (range, 2-19
years); 3 were male and 2 were female. Four conditioning regimens included alemtuzumab and 3 had
antithymocyte globulin. Of the 5 patients with NTM infections, 2 met the criteria for definite infection and
3 for probable infection. Of the 2 patients with definite NTM infection, 1 had disseminated disease with
Mycobacterium avium complex and the other had Mycobacterium chelonae catheter-related bloodstream
infection. The probable NTM infections were 1 skin infection with Mycobacterium kansasii and 2 lower
respiratory tract infections with M avium complex. Median time to NTM infection was 115 days (range,
14-269 days) after HSCT. Two patients had graft-versus-host disease at the time of NTM infection. All
5 patients received 3-4 antimycobacterial drugs and all NTM infections resolved. In summary, the
incidence of NTM infection in pediatric HSCT recipients appears similar to that described in adult HSCT
recipients and the outcome appears to be excellent with the proper antibiotic therapy. The increased use
of anti-T cell antibodies appears to be associated with an increased risk of NTM infections in pediatric
HSCT recipients. Multicenter studies are needed to identify the risk factors, early diagnostic criteria, and
optimal therapy.
© 2006 American Society for Blood and Marrow Transplantation
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NTM Infections in Pediatric Hematopoietic Stem Cell Transplantation 1189NTRODUCTION
Hematopoietic stem cell transplantation (HSCT)
ffers a potential cure for an increasingly wide spec-
rum of malignant and nonmalignant disorders but
pportunistic infections remain an important limiting
actor in determining outcome. During the past few
ears, in addition to bacterial, viral, and fungal infec-
ions in HSCT recipients, nontuberculous mycobac-
erial (NTM) infections are being reported more fre-
uently [1-4].
Nontuberculous mycobacteria are ubiquitous
athogens that can cause a broad spectrum of diseases
n immunocompetent and immunocompromised hosts.
pproximately 50 different mycobacterial species are
urrently considered etiological agents of human dis-
ase [5]. Nontuberculous mycobacteria have been re-
orted to cause pneumonia, lymphadenitis, skin and
oft tissue disease, skeletal infections, foreign body
nd central venous catheter infections, and dissemi-
ated infection [6].
Although contact with environmental mycobacte-
ia is regular and frequent, overt disease is uncommon
ecause of the low virulence of NTM organisms [6].
rotective immunity against infection with mycobac-
eria seems to depend primarily on T cells, which are
he main producers of interferon-, together with
atural killer cells in response to interleukin-12, which
s produced by dendritic cells and macrophages upon
ycobacterial invasion [7]. NTM disease has been
eported more commonly in immunocompromised
osts including patients with acquired immunodeﬁ-
iency syndrome, primary immunodeﬁciencies, and
fter chemotherapy or bone marrow and solid organ
ransplantation [1-4,8-17].
In a review of NTM infections in immunocom-
romised hosts, Doucette et al [13] reported inci-
ences of NTM infection among renal, heart, and
ung transplant recipients to be 0.16%-0.38%, 0.24%-
.8%, and 0.46%-2.3%, respectively. In the same re-
iew, the incidence of NTM infections among HSCT
ecipients was reported as 0.4%-4.9%. Most previous
eports of NTM in HSCT recipients have been de-
cribed in adult recipients and the highest incidence of
TM infection among adult HSCT recipients was
eported by Weinstock et al [2] who described 65%
f patients receiving T cell-depleted HSCT. HSCT
ecipients have severely impaired cell-mediated im-
unity because of their underlying disease, pre-
ransplantation chemotherapy and radiation, condi-
ioning regimen, graft-versus-host disease (GVHD),
nd GVHD prophylaxis and treatment. T cell-de-
leted HSCT is not being used in our institution.
ith the increased use of unrelated cord blood trans-
lantation with delayed engraftment [18] and increased
se of alemtuzumab and antithymocyte globulin (ATG)
n the conditioning regimens, we hypothesized that the sncidence of NTM infections in our pediatric population
ould be higher than reported by Weinstock et al. To
est our hypothesis we investigated the incidence of
TM infections and associated risk factors in a large
ohort of pediatric HSCT recipients treated between
anuary 2000 and December 2004 at Morgan Stanley
hildren’s Hospital of New York-Presbyterian at Co-
umbia University Medical Center.
ETHODS
atients
Between January 2000 and December 2004, 132
hildren underwent 169 HSCT at Morgan Stanley
hildren’s Hospital of New York-Presbyterian at Co-
umbia University Medical Center. One hundred
wenty-nine of these HSCT patients had malignant
isease and 40 did not. Patient characteristics are
isted in Table 1. All patients were enrolled in proto-
ols approved by the institutional review board in
ompliance with the Declaration of Helsinki. Alloge-
eic HSCT recipients were deﬁned as having high-
isk disease with1 of the following criteria: leukemia
n relapse, leukemia with induction failure, leukemia
n third complete remission or beyond, malignant
rogressive disease, and/or second allogeneic HSCT.
uman Leukocyte Antigen Typing
nd Allogeneic Donors
Human leukocyte antigen (HLA) typing for pa-
ients receiving stem cells from matched family donors
r umbilical cord blood (UCB) donors was performed
y serology for HLA-A and -B and by high-resolution
NA typing for DRB1. Patients receiving unrelated
dult donor peripheral blood stem cells (PBSCs) also
ad a 6/6 match with typing at class I (HLA-A and -B)
y serology and class II (HLA-DRB1) at high-resolu-
ion DNA typing. Matched family donors were re-
uired to be a 6/6 or 5/6 HLA match, and unrelated
CB donor units had to be a 6/6, 5/6 or 4/6 HLA
atch. UCB donor units were also required to have a
inimum of 1.5  107 nucleated cells of cryopre-
erved UCB unit/kg of recipient. Unrelated adult do-
ors were required to have a minimum of 5  106
D34 cells/kg and to be an 8/10, 9/10, or 10/10 HLA
atch (A, B, C, DRB1, DQB1).
For autologous HSCT, PBSCs were collected us-
ng apheresis. Endpoint for successful PBSC harvest-
ng was a collection of 5  106 CD34 cells/kg. For
euroblastoma patients, in case of detectable tumor
ells in the product by immunocytology, CD34 cells
ere selected using the Isolex 300i system (Baxter
mmunotherapy, Round Lake, Ill) or the CliniMacs
ystem (Miltenyi Biotec, Auburn, Calif).
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versus-host disease; MMF, mycophenolate mofetil; CSA, cyclo-
sporine; MTX, methotrexate.
E. Unal et al.1190onditioning Regimens
Conditioning regimens were myeloablative in
2.2% of patients, including all 64 autologous HSCT
ecipients, and nonmyeloablative (reduced intensity 
llogeneic HSCT) in 27.8%. Alemtuzumab-containing
onditioning regimens were used in 9.5% of recipients.
VHD Prophylaxis
Tacrolimus and mycophenolate mofetil (MMF)
ere administered as GVHD prophylaxis in 89.5% of
llogeneic HSCT recipients, as we previously de-
cribed [19]. Four patients who received matched un-
elated donor HSCT received methotrexate (15
g/m2 on day 1, 10 mg/m2 on days 3, 6, and
11) in addition to this regimen. Tacrolimus was
dministered intravenously (IV) at 0.03 mg/kg per day
s a continuous infusion or orally at 0.12 mg/kg per
ay in 2 divided doses starting on day 1 or on the
rst day of conditioning (protocol dependent). As we
reviously described, tacrolimus dosing was adjusted
o maintain tacrolimus steady-state or trough concen-
rations of 5-20 ng/mL (whole-blood enzyme-linked
mmunosorbent assay) [19].
MMF was administered daily starting on day 1
t a dose of 15 mg/kg per dose IV or orally twice daily,
s we previously described [19]. Beginning in January
002, MMF doses were adjusted to maintain myco-
henolic acid trough concentrations within a refer-
nce range of 1-3.5 g/mL. MMF was tapered or
iscontinued as per individual protocol, but not before
ay 28.
Other GVHD prophylaxis regimens included cy-
losporine/methylprednisolone (n  5, 4.8%), cyclo-
porine/methotrexate (n  5, 4.8%), and cyclosporine/
ethylprednisolone/methotrexate (n  1, 0.9%).
GVHD was graded according to the Glucksberg
nd Seattle consensus criteria [20,21]. The “rule of 9”
r burn chart was used to estimate extent of skin rash.
f a clinical diagnosis of acute GVHD (aGVHD) or
hronic GVHD (cGVHD) was made, histologic con-
rmation was obtained whenever possible.
upportive Care
All patients were hospitalized in protective isola-
ion, deﬁned as single hospital rooms with high-efﬁ-
iency particulate air ﬁltration system and reverse iso-
ation requiring strict hand degerming and mask use
y staff for unrelated HSCT patients. Beginning in
anuary 2001, liposomal amphotericin B (3 mg/kg per
ay IV over 2 hours) was administered to all patients
ho received allogeneic HSCT starting on day 0 until
ay 100, as we previously described [22]. Flucon-
zole was used as antifungal prophylaxis for the re-
aining patients. Additional anti-infective prophylaxis
gainst Pneumocystis carinii pneumonia, herpes simplexable 1. Patient Demographics (n  132)
ge (y), median (range) 5.25 (0.25-21.75)
ex, n (%)
Male 78 (59)
Female 54 (41)
iagnosis, n (%)
Malignant 129 (76.3)
ALL (3 CR1, 10 CR2, 4 CR3, 1 PD, 1 IF) 19
AML (7 CR1, 4 CR2, 1 CR3, 4 PD, 1 IF) 17
CML CP 6
HD (1 CR1, 6 CR2, 1 PR, 1 PR1, 2 PR2,
2 SD, 3 PD) 16
NHL (1 CR1, 1 CR2, 3 PR, 1 PR1, 3 SD,
1 PD) 9
Neuroblastoma (6 CR1, 2 CR, 13 PR, 4 PD) 25
Rhabdomyosarcoma (CR2) 2
Wilms tumor (5 CR2, 2 PR1, 3 PD, 1 SD) 11
Brain tumor
Medulloblastoma (CR1) 2
Ependymoma (5 SD, 2 PR) 7
Choroid plexus (1 PR, 3 SD) 4
Pineoblastoma (CR1) 3
Others 8
Nonmalignant 40 (23.7)
Aplastic anemia 11
Fanconi anemia 2
HLH/LCH 7
Sickle cell disease 3
-Thalassemia 5
WAS 2
SCID 2
Hurler syndrome 2
MDS 6
isk, n (%)
Average (all nonmalignant) 112 (66.3)
High 57 (33.7)
ransplant type, n (%)
Autologous 64 (37.9)
Allogeneic 105 (62.1)
ransplant source, n (%)
Family donor 42 (40)
6/6 HLA match 32
5/6 HLA match 10
Unrelated 63 (60)
Cord blood 59
4/6 HLA match 34
5/6 HLA match 18
6/6 HLA match 7
PB/BM 4
8/10 HLA match 1
9/10 HLA match 2
10/10 HLA match 1
onditioning regimen, n (%)
Myeloablative 122 (72.2)
Reduced intensity/nonmyeloablative 47 (27.8)
VHD prophylaxis, n (%)
Tacrolimus/MMF 94 (89.5)
CSA/steroids 5 (4.8)
CSA/MTX 5 (4.8)
CSA/MTX/steroids 1 (0.9)
LL indicates acute lymphoblastic leukemia; AML, acute myeloge-
nous leukemia; CML, chronic myelogenous leukemia; CP, chronic
phase; HD, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma;
CR, complete remission; CR1, ﬁrst complete remission; CR2,
second complete remission; CR3, third complete remission; PR,
partial remission; PR1, ﬁrst partial remission; PR2, second partial
remission; PR3, third partial remission; PD, progressive disease; IF,
induction failure; SD, stable disease; HLH, hemophagocytic lym-
phohistiocytosis; LCH, Langerhans cell histiocytosis; WAS,
Wiskott-Aldrich syndrome; SCID, severe combined immunodeﬁ-
ciency; MDS, myelodysplastic syndrome; HLA, human leukocyte
antigen; PB, peripheral blood; BM, bone marrow; GVHD, graft-irus, and cytomegalovirus [23], if indicated, was ad-
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NTM Infections in Pediatric Hematopoietic Stem Cell Transplantation 1191inistered. None of the patients received NTM pro-
hylaxis except 1 patient with severe combined immu-
odeﬁciency who had been on azithromycin since
iagnosis. All patients received hematopoietic growth
actors starting with sargramostim (granulocyte-mac-
ophage colony-stimulating factor, GM-CSF; 250
g/m2 per day IV daily) on day 0 within 3 hours of
tem cell infusion and continued until white blood cell
ount was 0.3  109 cells/l for 2 consecutive days.
atients were then switched to ﬁlgrastim (granulocyte
olony-stimulating factor; 10 g/kg per day IV daily)
nd tapered by 50% when the absolute neutrophil
ount reached 2.5  109 cells/L for 2 consecutive
ays, as we previously described [24].
efinition of NTM Disease
Deﬁnitions from the Centers for Disease Control
nd Prevention (CDC) were used as described in a
eport by Gaviria et al [1] to diagnose NTM disease
Table 2). The day of diagnosis of NTM infection was
eﬁned as the day on which the initial NTM isolate
as recovered or a diagnostic histopathologic speci-
en was obtained.
TM Isolation and Identification
All specimens for culture of mycobacteria were
btained for suspected opportunistic infection and ini-
ially digested and decontaminated with 2% NaLC-
aOH (Mycoprep BBL, Becton Dickinson, Sparks,
D), stained with AFB auramine-O ﬂuorescent stain
ENG Scientiﬁc Inc, Clifton, NJ), and inoculated
nto appropriate media, according to established pro-
ocol [25]. Samples were inoculated onto broth media
Mycobacterial Growth Indicator Tube, Becton Dick-
nson) and incubated in the automated BACTEC
able 2. Center for Disease Control and Prevention Deﬁnitions for My
. Lower respiratory tract disease
a. Definite—Respiratory symptoms compatible with pneumon
NTM from lower respiratory samples (ie, bronchoalveolar la
NTM or histologic evidence of tissue invasion by NTM.
b. Probable—Same criteria as definite but without concomitan
NTM.
c. Possible—Same as probable and identification of a copath
respiratory symptoms and pulmonary infiltrates after trea
against NTM.
. Catheter-related infection*
a. Definite—Typical symptoms (eg, exit site or tunnel erythem
b. Probable—Typical symptoms and isolation of NTM from the
. Other sites
a. Definite—Compatible symptoms, a positive culture for NTM
mycobacterial tissue invasion or a positive blood culture.
b. Probable—Compatible symptoms, a positive culture for NT
mycobacterial tissue invasion or positive blood culture.
TM indicates nontuberculous mycobacteria.
Infections were further categorized as exit site infection (2 cm of
infection (2 cm of inﬂammation from the catheter exit site ex
related bacteremia (without exit or tunnel infection).GIT 960 System. In addition, samples were plated
nto Lowenstein-Jensen slants and 7H11 selective and
onselective agar plates (Becton Dickinson) and incu-
ated (35°C, 5%-10% CO2) for 6-8 weeks.
After growth was observed, the mycobacteria were
dentiﬁed to species level by using commercially avail-
ble DNA probe assays (AccuProbe, Gen-Probe, San
iego, Calif) for identiﬁcation of Mycobacterium avium
omplex (MAC), Mycobacterium kansasii, and Mycobac-
erium gordonae and standard biochemical tests for
dentiﬁcation of other species.
TM Susceptibility Testing
Non-MAC NTM mycobacterial isolates were re-
erred to the University of Texas (Tyler, Tex) for testing
ith the following anti-NTM drug susceptibility panel:
mikacin, cefoxitin, ciproﬂoxacin, clarithromycin, doxy-
ycline, gatiﬂoxacin, imipenem, kanamycin, levoﬂoxacin,
inezolid, meropenem, minocycline, sulfamethoxazole,
nd tobramycin. MAC isolates were referred to the Na-
ional Jewish Medical and Research Center (Denver,
olo), where the following drugs were tested: amikacin,
iproﬂoxacin, clarithromycin, clofazimine, ethambutol,
evoﬂoxacin, rifabutin, rifampin, and streptomycin.
tatistical Analysis
Results are presented as medians with speciﬁed
anges of datasets. The Kaplan-Meier method was
sed to calculate the probabilities of incidences of
TM, aGVHD, cGVHD, and survival in children
nd adolescents who underwent HSCT from January
000 to 2004. Chronic GVHD was evaluated in the
roup of children and adolescents who underwent
SCT and were followed for18 months in the same
eriod, and incidence of cGVHD was calculated using
ial Disease [1]
monary infiltrates on chest radiograph, >1 positive culture for
r deep tracheal sputum), and a concomitant blood culture for
culture for NTM or histologic evidence of tissue invasion by
kely to account for the clinical picture or improvement of
of an alternative diagnosis without specific treatment
lence, fever) and positive blood culture for NTM.
ter site, tunnel, or tip.
a normally sterile site, and histologic evidence of atypical
a normally sterile site, but no histologic evidence of atypical
ation, ie, erythema, tenderness, or edema around exit site), tunnel
g along the subcutaneous tract of tunneled catheter), or catheter-cobacter
ia, pul
vage o
t blood
ogen li
tment
a, puru
cathe
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E. Unal et al.1192he Kaplan-Meier method. All group comparisons
ere made using the log-rank test. Statistical analysis
as performed with the Prism statistical program
GraphPad, San Diego, Calif).
ESULTS
emographic and Clinical Characteristics
From January 2000 to December 2004, 132 chil-
ren and adolescents with malignant and nonmalig-
ant disease underwent 169 HSCT procedures at our
nstitution (Table 1). Median follow-up was 827.5
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igure 1. A, Probability of developing grade III-IV aGVHD was
etermined by the Kaplan-Meier methods in patients after HSCT.
, Probability of developing cGVHD in patients followed 18
onths after HSCT determined by the Kaplan-Meier method.ays (range, 170-1958 days). Hraft-versus-Host Disease
The probabilities of aGVHD (at least grade II)
nd cGVHD (evaluated in children surviving 18
onths) in the allogeneic HSCT recipients were
8.5% (95% conﬁdence interval, 38.3-58.7) and
0.7% (95% conﬁdence interval, 11.3-30.1), respec-
ively (Figure 1A,B).
TM Infections
During this 5-year period, NTM infection was
iagnosed in 5 (3.8%) of 132 pediatric recipients of
SCT. None of the NTM infections was diagnosed in
atients after myeloablative plus autologous HSCT. The
ncidence of NTM in allogeneic HSCT was 6.4% (95%
onﬁdence interval, 0.8-11.9; Figure 2). Two had deﬁ-
ite NTM infection and 3 had probable NTM infec-
ion. Characteristics of patients with NTM infection
re listed in Table 3. Three of these patients (504-003,
05-002, and 509-008) were partly described by
icholson et al [26].
Three males and 2 females were diagnosed with
TM infection. Mean age was 8 years (median, 3
ears; range, 2-19 years). Diagnoses were chronic my-
logenous leukemia (CML) in chronic phase (CP) in 2
atients, neuroblastoma/post-SCT myelodysplastic
yndrome in 1, hemophagocytic lymphohistiocytosis
n 1, and severe aplastic anemia in 1. These 5 patients
nderwent 8 HSCT procedures (7 allogeneic and
autologous) and the donor sources for allogeneic
SCT were 6/6 sibling in 2, 5/6 sibling in 1, 6/6 UCB
n 2, and 5/6 UCB in 2. Two of 5 patients received1
SCT and for both patients NTM infection was
iagnosed after the second HSCT. Although 4 of 5
atients were diagnosed with GVHD at some point
uring their transplantation course, only 2 had active
VHD (1 with acute gut/skin GVHD and 1 with
xtensive cGVHD involving gut and skin) at the time
0 500 1000 1500 2000
0
20
40
60
80
100
NTM-allo HPSCT recipients
NTM-all HPSCT recipients
Day
igure 2. Incidence of NTM in all patients (solid line) receiving
SCT and in those after allogeneic HSCT (dashed line).
Table 3. Characteristics of Patients with NTM Infection (n  5)
Patient
Number
Age
(y) Sex Disease
Donor
Source
NTM
Culture/Biopsy
Sites NTM NTM Infection
Days from
HSCT to NTM
Infection
Antibiotic
Combinations
Days of
NTM Tx Outcome
504-003 3 F NBL/MDS UCB Gut biopsy, bone
marrow
culture, CSF
culture
MAC Definite/disseminated 14 Rifampin, levofloxacin,
amikacin,
azithromycin
119 Dead on
day
119,
VOD
505-002 19 M CML-CP AlloSib Blood culture M chelonae Definite/catheter-
related bacteremia
133 Imipenem, amikacin,
clarithromycin
468 Alive, NED
509-010 13 M SAA AlloSib Sputum culture MAC Probable/lower
respiratory tract
infection
269 Rifabutin,
azithromycin,
ethambutol,
levofloxacin
191 Alive, NED
505-004 3 F CML-CP AlloSib BAL culture MAC Probable/lower
respiratory tract
infection
127 Rifabutin, ethambutol,
azithromycin
40 Alive, NED
509-008 2 M HLH UCB Skin nodule
culture
M kansasii Probable/skin and soft
tissue infection
35 Rifampin, amikacin,
ethambutol,
levofloxacin,
azithromycin
153 Alive, NED
NTM indicates nontuberculous mycobacterium; HSCT, hematopoietic stem cell transplantation; NBL, neuroblastoma; MDS, myelodysplastic syndrome; CML, chronic myelogenous leukemia; CP,
chronic phase; SAA, severe aplastic anemia; HLH, hemophagocytic lymphohistiocytosis; UCB, umbilical cord blood; AlloSib, allogeneic sibling; CSF, cerebrospinal ﬂuid; BAL, bronchoalveolar
lavage; MAC, Mycobacterium avium complex; M chelonae, Mycobacterium chelonae; M kansasii, Mycobacterium kansasii; VOD, veno-occlusive disease; NED, no evidence of NTM disease/infection.
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E. Unal et al.1194f NTM diagnosis. For the 2 patients who had active
VHD at the time of NTM diagnosis, 1 had been
reated with prednisone and 1 had been treated with
rednisone, inﬂiximab, denileukin diftitox, rituximab,
nd etanercept. The median time from HSCT to
iagnosis of NTM infection was 115 days (range,
4-269 days). The median times from the submission
f the culture to a positive result for MAC, M kansasii,
nd M chelonae were 26, 6 and 5.5 days, respectively.
efinite NTM Infections
Disseminated MAC was diagnosed in a 3-year-old
emale after her second HSCT (Table 3). While on
reatment for NTM infection, the patient received a
econd allogeneic HSCT for graft failure and persis-
ent myelodysplastic syndrome 110 days after NTM
iagnosis. She died secondary to veno-occlusive dis-
ase of the liver and subsequent multiorgan failure 13
ays after this second allogeneic HSCT without evi-
ence of an NTM infection.
Catheter-related NTM bacteremia (M chelonae)
as diagnosed in a 19-year-old male patient with
ML in ﬁrst CP (Table 3). He received a 6/6 matched
llogeneic HSCT from his sibling with a conditioning
egimen consisting of busulfan (1.6 mg/kg  4 days),
udarabine (30 mg/m2  5 days), and alemtuzumab
54 mg/m2  5 days). He is currently alive without
vidence of an active NTM infection.
robable NTM Infections
Two patients were diagnosed with probable lower
espiratory tract NTM infections. A 13-year-old male
ith severe aplastic anemia received a 6/6 allogeneic
SCT from his brother (Table 3). The conditioning
egimen was cyclophosphamide (50 mg/kg  4 days),
udarabine (30 mg/m2 6 days), and ATG (2 mg/kg
days). He developed aGVHD of the gut and skin that
esponded to prednisone. Ground-glass opacities were
eported on a chest computed tomogram and sputum
ulture grew MAC 269 days after SCT. Bronchoal-
eolar lavage was negative and blood cultures re-
ained negative for NTM. He currently is alive and
ree of NTM infection.
A 3-year-old female received a 5/6 allogeneic
SCT from her sister for CML in CP (Table 3).
onditioning regimen was busulfan (4 mg/kg  4
ays), ﬂudarabine (30 mg/m2  5 days), and alemtu-
umab (54 mg/m2  5 days). Her course was compli-
ated by acute skin and gut GVHD followed by ex-
ensive cGVHD involving the skin and gut that was
esistant to steroid treatment. She had received com-
ination GVHD treatment with inﬂiximab and de-
ileukin diftitox followed by rituximab and etanercept
or refractory GVHD. Computed tomogram of the
hest demonstrated punctate nodular densities involv-
ng both lung ﬁelds. Bronchoalveolar lavage cultures irew MAC and M gordonae 127 days after HSCT. She
s currently alive 9 months after anti-NTM antibiotic
reatment with disappearance of the chest computed
omographic ﬁndings and no evidence of active NTM
nfection.
A 2-year-old male patient with hemophagocytic
ymphohistiocytosis developed graft failure and re-
eived a second allogeneic HSCT from a 5/6 UCB
onor with a conditioning regimen consisting of
usulfan (4 mg/kg  4 days), cyclophosphamide (60
g/kg  2 days), VP-16 (40 mg/kg  1 day), and
lemtuzumab (54 mg/m2  5 days; Table 3). A right
high skin nodule was noted on examination before
ngraftment. Biopsy of a right thigh skin nodule was
ositive for M kansasii 35 days after second allogeneic
SCT. He is currently alive and free of NTM infec-
ion after anti-NTM antibiotic treatment.
urvival
Kaplan-Meier survival curves for patients with
TM infection and all patients who underwent allo-
eneic HSCT are included in Figure 3. Probabilities
f overall survival in all patients (Figure 3A) and those
n average- and high-risk groups (Figure 3B) were
8% (95% conﬁdence interval, 49.1-100), 68.4% (95%
onﬁdence interval, 58.6-78.3), and 33.7% (95% conﬁ-
ence interval, 17.5-49.9), respectively. Survival among
atients with NTM (Figure 3C) was 80.0% (95%
onﬁdence interval, 44.9-100). There were no deaths
econdary to NTM infection.
ISCUSSION
This is the largest pediatric series of HSCT recip-
ents to report the incidence and outcome of NTM
isease. In this series, 5 of 132 (3.8%) children were
iagnosed with an NTM infection and, as expected,
he risk was higher (6.4%) among allogeneic HSCT
ecipients. The incidence after autologous HSCT was
egligible. As evidence of the diagnostic difﬁculties
nherent in NTM infections, deﬁnite infection was
iagnosed in only 2 patients, and probable infection
as diagnosed in 3. Outcome in the patients with
TM infections appeared to be excellent because all
nfections resolved with medical treatment with anti-
TM antimicrobial agents.
The incidence of NTM infection in our allogeneic
SCT recipients (6.4%) is higher than that in the
dult allogeneic HSCT recipients reported by Wein-
tock et al [2] (4.9%). This higher incidence may have
een secondary to the use of alemtuzumab and/or
abbit ATG, a large number of unrelated donors,
nd/or active GVHD treatment with systemic ste-
oids. GM-CSF is an earlier and broader-acting CSF,
hich also induces more T helper 1 and dendritic cellmmune subsets preferentially in addition to mono-
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olony-stimulating factor [24] , which might play an
mportant role in the host defense against NTM in-
ections. Theoretically, the use of GM-CSF may have
revented some of the early NTM infections.
An increase in NTM infections in recent years has
een reported [13] and is thought to be due to in-
reased patient survival, increased awareness of NTM,
nd enhanced diagnostic capabilities.
In a recent review of NTM infections in HSCT
ecipients, the incidence ranged from 0.4% to 4.9%
13]. In the case series reported by Roy and Wisdorf
3], the incidence was only 0.4%, but 46.8% of their
atients were 18 years of age, which potentially
xplained the lower incidence of infections. In con-
rast, Weinstock et al [2] reported that 4.9% of allo-
eneic HSCT recipients were diagnosed with a deﬁ-
ite or probable NTM infection. The increased
ncidence was potentially explained by the use of
cell depletion, an increased awareness of NTM, and
ncreased diagnostic testing and the frequency of in-
ections caused by M haemophilum [2,9].
Three large series in the literature have reported a
igher incidence of NTM infections in unrelated al-
ogeneic HSCT recipients: related versus unrelated,
.22% versus 1.0% [1], 0.36% versus 0.54% [3], and
.7% versus 5.3% [2]. The increased use of unrelated
ismatched donors and immunosuppressive medica-
ions in recent years may also contribute to this in-
rease in NTM. Three of our patients with NTM
nfection had received matched related sibling trans-
lants. In addition, the somewhat higher incidence in
ur population could be secondary to the immuno-
uppressive treatment regimens our patients received.
lthough the limited number of patients with NTM
t our institution did not allow an analysis of risk
actors, the use of alemtuzumab in the conditioning
egimen before the diagnosis of NTM in 3 of 5 pa-
ients is striking. Alemtuzumab is a humanized mono-
lonal antibody directed against the CD52 antigen
hat is expressed on virtually all lymphocytes (T lym-
hocytes more prominently than B lymphocytes) and
onocytes [27]. It is used for in vivo and in vitro T cell
epletion and for the treatment of lymphoma, auto-
mmune disorders, and GVHD because of its pro-
ound effect on T cells [28]. Reactivation of M xenopi
ulmonary infection, systemic tuberculosis, and dis-
eminated disease with M bovis immediately after ad-
inistration of alemtuzumab have been reported [29-
1]. Thus, alemtuzumab may be an additional risk
actor for developing NTM in HSCT recipients.
NTM infections of the lower respiratory tract can
e very difﬁcult to diagnose. The diverse clinical spec-
rum, coinfections, the delay until a positive culture
ecause of the slow growth of many of these organ-
sms, and the difﬁculty distinguishing colonizationA
0 500 1000 1500 2000
0
20
40
60
80
100
Day
B
0 500 1000 1500 2000
0
20
40
60
80
100
Average risk HSCT recipients
High risk HSCT recipients
Day
P
ro
ba
bi
lit
y
of
S
ur
vi
va
l
C
0 300 600 900 1200
0
20
40
60
80
100
Day
igure 3. A, Probability of overall survival determined by the
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c
t
s
s
r
a
p
i
v
c
t
H
p
H
v
H
p
a
a
c
r
i
b
p
“
d
6
d
p
m
B
c
o
N
H
t
t
a
o
c
N
a
t
p
t
s
d
t
l
p
t
r
t
w
t
I
t
s
S
f
t
p
i
s
a
e
A
C
S
M
t
r
n
t
R
1
E. Unal et al.1196omplicating the diagnosis of pulmonary NTM infec-
ions. Although the CDC criteria were used in this
tudy [1], it is possible that some cases were misclas-
iﬁed because any positive culture from lower respi-
atory tract secretions in combination with radiologic
nd clinical symptoms is sufﬁcient for the diagnosis of
robable or possible disease. Diagnostic criteria deﬁn-
ng “infection” could also be a reason why statistics
ary among studies. Thus, it is possible that 2 of our
ases were only colonized and not truly infected, al-
hough no copathogens were identiﬁed.
The characteristics of NTM infections in adult
SCT recipients are somewhat different when com-
ared with NTM infections in our series of pediatric
SCT recipients. Doucette and Fishman [13] re-
iewed 93 previously reported NTM cases in adult
SCT recipients. The median time between trans-
lantation and presentation was 4.6 months, median
ge was 32 years, and the incidence was equal for male
nd female patients. GVHD was present in 46% of
ases. The most common presentation was catheter-
elated infection (37%) and the most frequent species
solated was rapidly growing NTM, with M fortuitum
eing the most common followed by MAC. Sixty-two
ercent of the cases were reported as “resolved” or
cured” with medical therapy. In 7.5% of patients,
eath was attributed to NTM disease. In our series,
0% of our patients with NTM were male, the me-
ian time to infection was 3.8 months, and 40% of
atients had GVHD at the time of infection. The
ost frequent species detected in our series was MAC.
acteremia or catheter-related infections, which are
aused more by rapidly growing NTM, were less in
ur series. In our series, no deaths were attributed to
TM infection.
The optimal treatment for NTM infections in
SCT recipients remains undeﬁned. Four of our pa-
ients were started on 3 or 4 anti-NTM antibiotics and
he ﬁfth patient with M chelonae infection received 2
ntibiotics after catheter removal. The mean duration
f treatment for the 3 patients who completed the
ourse was 270 days. Thus, treatment regimens for
TM are often complex because multidrug regimens
re required, with numerous toxicities and the poten-
ial to affect the metabolism of other treatments. Em-
iric treatment is usually begun before susceptibility
esting results and the role of susceptibility testing is
till evolving. The duration of treatment is largely
erived from other patient populations and reﬂects
he species, site of infection, and clinical, microbio-
ogic, and radiologic responses to treatment [13]. De-
ending on the severity of the infection, decreasing
he immunosuppressive regimens might be necessary.
In summary, NTM infections do occur in pediat-
ic HSCT recipients and the incidence is similar to
hat reported in the adult population. Although there
as a higher incidence in allogeneic HSCT recipients,he incidence after autologous HSCT was negligible.
n this small series, the outcome was excellent, al-
hough it is possible that some patients were misclas-
iﬁed with disease when they had only colonization.
usceptibility to NTM infection is most likely multi-
actorial and identifying the risk factors will be impor-
ant to optimize management in this complex patient
opulation. Because of the relative rarity of NTM
nfections, multicenter studies are needed to develop
trategies to identify risk factors and optimize man-
gement of these NTM infections in HSCT recipi-
nts.
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